Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

CON earnings analysis

Filed May 7, 2026 · Our reading of the company's report

The latest report

Concentra Group Holdings Parent, Inc. reported a strong Q1 2026 with revenue of $569.6 million, exceeding estimates by 2.87%, and EPS of $0.40, surpassing expectations by 17.65%. This represents a 13.7% growth in…

Read full summary

Concentra Group Holdings Parent, Inc. reported a strong Q1 2026 with revenue of $569.6 million, exceeding estimates by 2.87%, and EPS of $0.40, surpassing expectations by 17.65%. This represents a 13.7% growth in revenue year-over-year, driven by increased patient visits and efficient operations.

Read the original on SEC.gov

From revenue to operating profit

Where each $100 of revenue went in this report.

Of every $100 of revenue Cost of sales $70 Operating expenses $13 Left as operating profit $17

Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.

How we read each report

Our analysis across the last few reports.

Read as bullish Read as bearish Nov 2025 May 2026

Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.

Reported figures

Earnings per share
$0.4
Segment
Occupational health centers: 91%
Segment
Onsite health clinics: 7%
Segment
Other businesses: 2%

What stood out

  • Revenue Growth

    Revenue increased 13.7% from $500.8M in Q1 2025 to $569.6M in Q1 2026.

  • EPS Surprise

    Reported EPS of $0.40 beat estimates of $0.34 by 17.65%.

  • Improved Margins

    Gross margin improved to 29.9% from 28.7%, demonstrating better cost management.

  • Higher Adjusted EBITDA

    Adjusted EBITDA rose to $120.7M, up from $102.7M, marking a 17.5% increase.

  • Increased Patient Visits

    Total patient visits increased by 6.7%, reaching 3,419,091 in Q1 2026.

  • Share Repurchase Program

    Repurchased $15M worth of shares during the quarter, with $65M remaining for future buybacks.

What to watch

  • High Debt Levels

    Total debt remains high at $940.5M with significant interest expense of $26M.

  • Regulatory Scrutiny

    The company faces risks from increased regulatory scrutiny impacting operations.

  • Litigation Risks

    Ongoing litigation may expose the company to substantial liabilities, affecting future cash flows.

Management's outlook

Management raised full-year revenue guidance to $2.275B-$2.375B and adjusted EBITDA to $460M-$480M.

Earlier filings 2

10-K · February 26, 2026

Concentra (CON) presents a strategy focused on scale in occupational health, expanding onsite clinic capability and telemedicine while pursuing M&A to grow reach. 2025 revenue was $2,163.4 million, driven primarily by…

10-Q · November 6, 2025

Concentra reported Q3 revenue of $572,800 (in thousands) and GAAP diluted EPS of $0.38 for the three months ended September 30, 2025. Revenue rose year-over-year from $489,638 (in thousands) while gross margin remained…

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.